The Wisconsin Tamoxifen Study: Toxicity in Node-Negative Postmenopausal Women
Author:
- 1 January 1988
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 6 (5) , 601-605
Abstract
I would like to share some thoughts about where we are going in our tamoxifen research program at Wisconsin. We are looking toward the possibility of long-term use of tamoxifen as adjuvant therapy and, as a chemosuppressive agent in healthy women who do not have breast cancer, but are at increased risk for this disease. With these possibilities in mind, we are carefully assessing the biological effects of tamoxifen.Keywords
This publication has 4 references indexed in Scilit:
- Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trialBreast Cancer Research and Treatment, 1986
- Anti‐estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life‐table analysis and steroid hormone receptor statusWorld Journal of Surgery, 1985
- The Christie Hospital Tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma - 7-yr resultsEuropean Journal of Cancer and Clinical Oncology, 1985
- ADJUVANT HORMONAL CHEMOTHERAPY IN EARLY BREAST CANCER: EARLY RESULTS FROM A CONTROLLED TRIALThe Lancet, 1984